-

06:04:46 AM

LPCN Stock News

LPCN - Lipocine Inc

01/12/21 8:00 AM

Nasdaq : LPCN

clinical trial

Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline results from its LiFT (" L iver F at intervention with oral T estosterone") Phase 2 clinical study

RHEA-AI

neutral

01/04/21 8:00 AM

Nasdaq : LPCN

conferences

Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that the Company will participate in the H.C. Wainwright BioConnect 2021 Conference, being held virtually on January 11-14,

RHEA-AI

neutral

12/30/20 8:00 AM

Nasdaq : LPCN

Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is enrolling patients into an open label extension to the ongoing LPCN 1144 Phase 2 LiFT study based on

RHEA-AI

neutral

12/29/20 8:00 AM

Nasdaq : LPCN

Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C. Bryson of the United States District Court of Delaware has postponed the February 8, 2021 jury

RHEA-AI

neutral

12/08/20 8:49 PM

Nasdaq : LPCN

Lipocine Announces Tentative Approval of TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to TLANDO, its oral testosterone

RHEA-AI

very positive

12/08/20 8:40 PM

Nasdaq : LPCN

Lipocine Announces Deletion of Unauthorized Changes to Company's Website

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent contractor posted on Lipocine's website ( www.lipocine.com), without authorization from Lipocine,

RHEA-AI

neutral

12/04/20 5:45 PM

Nasdaq : LPCN

Lipocine Provides New Regulatory Update on TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is continuing to work towards

RHEA-AI

neutral

11/10/20 8:00 AM

Nasdaq : LPCN

Lipocine Announces Third Quarter 2020 Financial and Operational Results

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update.Third Quarter and

RHEA-AI

neutral

11/06/20 8:00 AM

Nasdaq : LPCN

Lipocine Provides Regulatory Update on TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is working towards taking action on

RHEA-AI

neutral

11/05/20 8:00 AM

Nasdaq : LPCN

conferencesclinical trial

Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present a poster with results from a preclinical study investigating LPCN 1144 treatment on hepatic fibrosis

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next

LPCN Data

Websitewww.lipocine.com
CeoMahesh Patel
Security nameLipocine Inc
Issue typecs
Sic code2834
Employees11
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address675 S Arapeen Dr Ste 202
StateUtah
CitySalt Lake City
Zip84108-1295
CountryUS
Phone18019947383

About Lipocine Inc

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the U.S. Food and Drug Administration (the 'FDA') for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a Phase 2 clinical evaluation when administered once daily or twice daily, TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA.